# Nuclide record cabozantinib (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/cabozantinib/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "cabozantinib" ;
  schema:name "Cabozantinib"@en ;
  schema:description "A pill that blocks both blood-vessel growth and the MET escape pathway, used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers."@en ;
  schema:url <https://nuclide.cc/drugs/cabozantinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cabozantinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q795057> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cabozantinib> ;
  nuclide:status "approved" ;
  nuclide:modality "Small-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)" ;
  schema:alternateName "Cabometyx" ;
  nuclide:approval "US 2012: Medullary thyroid cancer (Cometriq)", "US 2016: Advanced RCC", "US 2019: HCC previously treated with sorafenib", "US 2025: Advanced pancreatic and extra-pancreatic neuroendocrine tumours after prior therapy (CABINET)", "US 2017: First-line advanced RCC (CABOSUN)", "US 2021: First-line advanced RCC with nivolumab (CheckMate 9ER)", "EU 2014: Cometriq for medullary thyroid cancer; 21 Mar 2014. Cabometyx (RCC) Sep 2016" ;
  nuclide:indications <https://nuclide.cc/indications/hcc/>, <https://nuclide.cc/indications/rcc/>, <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/thyroid/> ;
  nuclide:trials <https://nuclide.cc/trials/cabinet/>, <https://nuclide.cc/trials/nct03690388/> .